Antibiotic Development Pipeline and Strategies Analysed in New In-Demand Study by Biopharm Reports Available at MarketPublishers.com
18 Jan 2012 • by Natalie Aster
LONDON – While antibiotics are effective for the major of infections, increasing resistance in some pathogens threatens to undermine the few remaining drugs that are still effective against them. In the last decade, the capacity to target pathogens has been undermined by a lack of innovation, which has seen a 60% fall in the numbers of new approvals and few novel molecules. However, this trend is changing.
New market research report "Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance" prepared by Biopharm Reports has been recently published by Market Publishers Ltd.
Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance
Published: January, 2012
Price: US$ 2.300,00
The report features a comprehensive overview of global antibiotic resistance, the antibiotics pipeline and new strategies to target resistance mechanisms. It identifies 109 antibiotics in the development pipeline, approximately 70% of which are in early development. Moreover it examines 209 marketed antibiotics for the treatment of bacterial and fungal infections.
More new market research reports by the publisher can be found at Biopharm Reports page.